Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

from Reuters: Health News http://ift.tt/2Es6Ebw